Anexon, Inc. is a Focused Company developing an alternatively spliced variant of brain natriuretic peptide, ANX-042, for the treatment of patients with chronic heart failure and kidney dysfunction. The company was established based on discoveries and technology licensed from the Mayo Clinic, and it is funded by HealthCare Ventures and Mayo Clinic Foundation for Medical Education and Research.